MOH · Molina Healthcare, Inc. · Stock research

Current Thesis

The fundamental leg passed its test; the price leg that expressed it did not hold. Q2 2026 (released after the close on 2026-07-22, call 2026-07-23) delivered adjusted EPS of $1.51 against GAAP $1.19 on $10.2B of premium revenue, and full-year adjusted EPS guidance went up $0.25 to at least $5.25 — the first raise of this cycle against the ≥$5.00 floor set in the Q4 2025 guide-slash. Since then the tape has gone the other way. Shares fell 4.4% on 2026-08-17 to $203.06 with no company announcement or filing in that window, and the week ending 2026-08-21 closed at $200.29 — below the $205 shelf left by the late-June breakout gap, which is the level the prior frame identified as the structural break. RSI(14) is 54.6 versus 63.3 measured to 2026-08-14; the three-month price change has compressed to +8.8% from +14.8% over the same span a week earlier. Price sits 17.5% under the $242.88 52-week high. What an investor is buying from here is management's 2027 earnings-power framing above $10 per share (stated on the 2026-07-23 call, not a formal guide) against a Hold-dominant sell-side whose aggregated target sits at the market, with the next dated company event roughly nine weeks out.

Bullish and bearish views on Molina Healthcare, Inc.

The model's bull view on Molina Healthcare, Inc. (MOH), in brief: The trough number moved up (2026-07-22): FY26 adjusted EPS guided to ≥$5.25 from ≥$5.00, with GAAP guidance also raised. The bear view: Marketplace deteriorated faster than the repricing fixed it. Both cases follow in full.

Bull Case

• The trough number moved up (2026-07-22): FY26 adjusted EPS guided to ≥$5.25 from ≥$5.00, with GAAP guidance also raised. Guidance rose into the print investors feared.
• Medicare duals inflected (call, 2026-07-23): FY Medicare MCR guidance cut to 92.2% from 94.0%, lifting segment EPS contribution by $1.50 to $0.25 — the largest single swing inside the raise.
• Medicaid cost trend held (Q2, 2026-07-22): Medicaid MCR 92.7% against an FY guide of 92.9%; consolidated FY MCR guide untouched at 92.6% even as Q2 consolidated MCR ran 92.2% versus 90.4% a year earlier.
• A stated 2027 number (call, 2026-07-23): earnings power above $10 per share, built from roughly $4.50 embedded in the Florida contract and the MA-PD reversal plus about $0.75 from Marketplace returning to break-even. This is the forward leg; it is management framing and carries no guidance status.
• Unpriced policy optionality: the House passed a three-year extension of the enhanced ACA premium tax credits 230–196 on 2026-01-08 (AHA, Ballotpedia coverage); the Senate has not acted. Marketplace is currently carried at a −$0.75 FY EPS contribution, so a Senate move re-prices the segment most damaged in the Q2 reset.
• July fair-value marks sit above spot: RBC $248 (2026-07-09), Truist $250 (2026-07-14), Wells Fargo $235 (2026-07-13), TD Cowen $230 (2026-07-14), BofA $250 on the 2026-06-24 Underperform→Buy double upgrade. Caveat below: those marks do not reconcile with the mid-August aggregations.

Bear Case

• Marketplace deteriorated faster than the repricing fixed it. FY Marketplace MCR guidance was raised to 90.0% from 85.5% on 2026-07-23, and CEO Joseph Zubretsky told the call, "We underestimated the stickiness of high-cost members," despite rate increases of 15%–45%. The segment swung from a projected +$0.75 contribution to −$0.75.
• The ACA book is shrinking to a stub. Molina expects roughly 250,000 ACA enrollees at year-end 2026, with further market exits planned for 2027 (Healthcare Dive, 2026-07-23). Enhanced premium tax credits expired 2025-12-31 and roughly 3 million people have left the exchanges since.
• The sell-side mean has drifted to the price. An aggregation summarized on 2026-08-18 showed a consensus Hold with a mean target of $202.44 and a $129–$220 range; a different aggregation accessed 2026-08-15 showed a mean near $209 with a $147–$266 range and a 15 hold / 3 buy / 1 sell mix. The two are not reconcilable with the named July targets — $250 exceeds the top of the 2026-08-18 range — so at least one constituent set is stale or partial. Both means bracket rather than clear the 2026-08-21 close of $200.29.
• Ratings never followed the targets. July's raises to $230–250 kept Hold/Equal-Weight/Sector-Perform labels, and Barclays cut to $184/Underweight on 2026-07-09.
• Sector cost trend prices MOH first. On Elevance's mid-July Q2 report, Health Benefits adjusted operating margin fell to 3.6% from 5.0% and segment operating profit dropped by nearly half; MOH traded down as much as 9% premarket that morning, the steepest move among major peers.
• Membership is contracting. Q2 total membership declined year over year even as EPS beat and guidance rose, against a base of roughly 4.9 million members.

Setup & Price Structure

• Reference close 2026-08-21: $200.29, 17.5% below the $242.88 52-week high, RSI(14) 54.6, three-month price change +8.8%.
• Sequence into the break: $212.43 on 2026-08-14 → a 4.4% decline on 2026-08-17 to $203.06 (per the GuruFocus summary carried 2026-08-18) → $200.29 on 2026-08-21. No Form 4 or other filing appears in the recent window, and no company release explains the 08-17 move; the available coverage names none.
• The $205 area marked the floor of the late-June breakout gap. With that gone on a weekly close, the next observable structure below is the $188–192 shelf that contained the name before the June move.
• The narrative is maturing. Dating it: the last company-generated headline is the 2026-07-23 call; intervening coverage is a 15-year backward-looking-return piece (2026-08-13) and a whale-activity options-flow item (2026-08-18); aggregated targets sat at the price on 2026-08-18; nothing dated moves the number until roughly 2026-10-22. The narrative is well known and still supported by the Q2 numbers, while the flow that carried June–July has stopped paying.
• Crowding and positioning observables: mean target $202.44 versus a $200.29 close (2026-08-18 / 2026-08-21); ratings mix dominated by Hold; approximately 98.5% of float held by institutions (GuruFocus, 2026-08-18) on a market capitalization near $10.7B; S&P MidCap 400 membership since the 2026-07-16 reconstitution, so passive sponsorship runs through mid-cap vehicles; no earnings date inside the next 30 days; no insider transactions or equity issuance visible in the recent filing feed.

Catalyst Calendar (next 30 days)

• 2026-08-23 → 2026-09-22: no confirmed company-scheduled event. Nothing dated is on the calendar in this window; the datapoints that arrive are peer guidance updates and state Medicaid rate actions, which have no schedule.
• ~2026-10-22 (est.): Q3 2026 results, released after the close with the call the following morning. First test of the ≥$5.25 FY26 adjusted EPS guide, the 92.6% consolidated MCR guide, and whether the Marketplace loss stops at −$0.75.
• 2026-11-01: ACA open enrollment opens for the 2027 plan year — sizes the Marketplace book against the ~250,000 year-end 2026 enrollee expectation and the planned 2027 exits.
• ~2026-12-01 (est.): twice-a-year Medicaid eligibility redeterminations begin, a recurring attrition mechanism on the base carrying the $5.75 Medicaid segment EPS contribution.

Elapsed catalysts

• Undated, live: Senate action on the enhanced-premium-tax-credit extension the House passed 230–196 on 2026-01-08. No vote is scheduled; it is optionality, not a date. (passed 230d ago)

What Would Change Our Mind

The structure that carried the June–July leg is already gone: the week ending 2026-08-21 closed at $200.29, under the $205 gap floor, which resolved the prior frame's break condition on the downside. The question now is whether the $188–192 pre-breakout shelf holds. A weekly close below $188 would take out that shelf and end the trough-recovery leg outright, at which point the label moves from maturing toward failed. On the other side, a weekly close back above $213 would reclaim the broken gap and put the June structure back in play. On the fundamentals, the specific datapoints that break the thesis at the ~2026-10-22 print: FY26 adjusted EPS guided back under $5.25, the consolidated MCR guide lifted above 92.6%, Medicaid MCR printing above the 92.9% FY guide, or Marketplace MCR guided above 90.0%. And there is a quieter failure mode: if the October print holds every number and the shares still cannot reclaim $213, the market is declining to underwrite the >$10 2027 framing, which is the only remaining reason to own the story.

Correlation Notes

• Moves with CNC, ELV, UNH and CVS on shared cost-trend headlines; the mid-July Elevance Q2 produced a premarket decline of as much as 9% in MOH, larger than any major peer, reflecting the Medicaid concentration.
• Policy beta is the dominant non-earnings driver: ACA subsidy legislation, CMS Medicare rate notices, and state Medicaid rate actions each move the name without a company event.
• Index membership sits in the S&P MidCap 400 since 2026-07-16; flow arrives through mid-cap vehicles rather than large-cap ones, which thins the bid on sector-wide risk-off days.
• Essentially no linkage to the AI/mega-cap complex driving broad index returns; the 17.5% distance from the 52-week high is sector-specific damage.